PharmaShots | Incisive News in 3 Shots

Subscribe Now

PNH

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

May 17, 2021

Novartis' Iptacopan (LNP023) Receives the US FDA's Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G

Novartis' Iptacopan (LNP023) Receives the US FDA's Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation...

December 16, 2020

Samsung Bioepis Initiates Recruitment of Patients in P-III Study for SB12 (biosimilar- eculizumab) to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH) in India

Samsung Bioepis Initiates Recruitment of Patients in P-III Study for SB12 (biosimilar- eculizumab) to Treat Paroxysmal Nocturnal H...

August 16, 2019

Generium and Selexis Launch Eculizumab Biosimilar for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Hemolytic Uremic Syndrome (aHUS) in Russia

Generium and Selexis Launch Eculizumab Biosimilar for Paroxysmal Nocturnal Hemoglobinuria (PNH) and Hemolytic Uremic Syndrome (aHU...

April 9, 2019

Alexion's Ultomiris (Ravulizumab-Cwvz) Receives FDA Approval in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion's Ultomiris (Ravulizumab-Cwvz) Receives FDA Approval in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

December 27, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us